Fact CheckerSign in

NCT05313191Recruiting

Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors

Source: ClinicalTrials.gov · Last updated 13 Apr 2026

Brief summary (registry, in English)

The goal of this clinical research trial is to study the use of differing investigational doses and scheduling for Proton Therapy for tumors previously treated with radiation therapy. Generally, when patients are first treated for cancer with radiation therapy, they are treated with traditional photon (or x-ray) radiation therapy, which uses high-energy waves to kill tumor cells. In some cases, the cancer either returns or a new tumor can present in a different part of the body. With the usual radiation treatment, the photon beams travel all the way through the body. As a result, healthy tissues in front of and behind the tumor are exposed to radiation. Physicians who treat these cases where the tumor has returned often use a much lower dose of radiation to prevent patients from experiencing serious and long-term side-effects. This dose is often not strong enough to destroy the cancerous tumor. Alternatively, they may also treat a smaller area than would be indicated for complete tumor eradication, again in an attempt to prevent serious and long-term toxicities, but at the cost of optimally treating the cancer. Proton therapy, however, may offer a chance to safely deliver a more effective dose and volume of radiation as it is more targeted and can spare healthy tissues surrounding the tumor. The reason we are conducting this research study is to look at whether Proton therapy can be a better way to treat reoccurring tumors in patients who have previously received radiation therapy to the same area, compared to treatment approaches used to date.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
1800 (estimated)
First submitted
21 Mar 2022
Start date
24 Jan 2022
Primary completion date
31 Jan 2028
Lead sponsor
The New York Proton Center
NCT number
NCT05313191

What you commit to

  • Study type: Interventional
  • Planned participants: 1800
  • From 24 Jan 2022 to the primary completion date, 31 Jan 2028
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Non malignant systemic disease that would preclude the patient from receiving study treatment or would prevent required follow up.

Other illness

  • History of active connective tissue disorder (i.e., systemic lupus erythematosus, scleroderma), dermatomyositis, xeroderma pigmentosum

Age

  • Prior invasive non study malignancy unless disease free for ≥ 3 years
    • Non melanoma skin cancer, low risk prostate cancer, well differentiated thyroid cancers, in situ carcinomas of the oral cavity, cervix, and other organs, and tumors that are not thought to impact the life expectancy of the patient are permissible.

Who the study is looking for

  • Age 18 years
  • Patient provides study specific informed consent prior to study entry.
  • Documented history and physical exam within 90 days prior to registration.
  • ECOG PS 0, 1, or 2 within 90 days prior to registration

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
The New York Proton Center
Coordinator of this site? Confirm its status
New YorkUnited StatesRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.